Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avacta GroupAVCTF +3.14%22 Days Sales Outstanding is 9,685.71 as of Dec. 2025, which is 8841% above its 10-year median of 108.33. GuruFocus rates AVCTF with a GF Score™ of 22/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 835 Biotechnology companies, Avacta Group ranks worse than 99.16% on this metric.
Avacta Group's average Accounts Receivable for the
six
months ended in Dec. 2025 was $4.03 Mil. Avacta Group's Revenue for the
six
months ended in Dec. 2025 was $0.08 Mil.
Hence, Avacta Group's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 9,685.71.
The historical rank and industry rank for Avacta Group's Days Sales Outstanding or its related term are showing as below:
AVCTF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.22 Med: 108.33 Max: 10481.64
Current: 9666.04
During the past 13 years, Avacta Group's highest Days Sales Outstanding was 10481.64. The lowest was 27.22. And the median was 108.33.
AVCTF's Days Sales Outstanding is ranked worse than 99.16% of 835
companies
in the Biotechnology industry
Industry Median: 68.94
vs AVCTF: 9666.04
Avacta Group's Days Sales Outstanding
declined
from Dec. 2024 (24,472.74) to Dec. 2025 (9,685.71).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
Avacta Group (OTCPK:AVCTF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Avacta Group Days Sales Outstanding Related Terms
Avacta Group Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Avacta Group's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVCTF vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Avacta Group's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Avacta Group's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 9,685.71 mean?
Avacta Group (AVCTF) has a Days Sales Outstanding of 9,685.71 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Avacta Group and its competitors. This is 8841% above median its historical median of 108.33. Over the past decade, Avacta Group's Days Sales Outstanding has ranged from 27.22 to 10,481.64. According to the industry distribution chart, Avacta Group ranks #828 out of 835 companies in the Biotechnology industry, placing it in the top 99.2%.
Is Avacta Group's Days Sales Outstanding too high?
Avacta Group's current Days Sales Outstanding of 9,685.71 is 8841% above median its 10-year median of 108.33. Over the past 10 years, this metric has ranged from a low of 27.22 to a high of 10,481.64. The Biotechnology industry median Days Sales Outstanding is 68.94. Avacta Group's value of 9,685.71 is 13949.5% above this industry median. Based on the distribution chart, Avacta Group ranks #828 out of 835 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avacta Group has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #828 out of 835 companies for Days Sales Outstanding. This places Avacta Group in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. Avacta Group's value of 9,685.71 is 13949.5% above this benchmark. Historically, Avacta Group's own Days Sales Outstanding has ranged from 27.22 to 10,481.64 over the past decade. While the company's 10-year median is 108.33 vs. the industry median of 68.94, Avacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avacta Group's current Days Sales Outstanding of 9,685.71 is 13949.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Avacta Group and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current Days Sales Outstanding is 9,685.71, which is 8841% above median its own 10-year median of 108.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $0.93 — trading 42.8% above its estimated fair value. The current Days Sales Outstanding is 9,685.71, which is 8841% above median its 10-year median of 108.33 and 13949.5% above the Biotechnology industry median of 68.94. Avacta Group's overall GF Score™ is 22/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Avacta Group (AVCTF), the current Days Sales Outstanding is 9,685.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (AVCTF) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of $0.93 is trading 42.8% above its estimated GF Value™ of $0.65.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for AVCTF:
Days Sales Outstanding: 9,685.71 (8841% above median its 10-year median of 108.33)
GF Value™: $0.65 vs. price of $0.93 (42.8% above fair value)
Industry Position: 13949.5% above the Biotechnology median (#828 of 835)
No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
22GF Score
Get the complete analysis for AVCTF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCTF has been successfully added to your 
